Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →In 2021 the American Cancer Society projected 235,760 new cases of lung and bronchus cancer in the United States and 131,880 lung cancer deaths, making lung…
Merck reported full-year 2021 Keytruda (pembrolizumab) sales of $17.186 billion, up 20% year-over-year, with growth driven by uptake in earlier lines of NSCLC,…
Bristol Myers Squibb has returned rights to AGEN1777 to Agenus, terminating the 2021 license agreement and ending the Fc-enhanced anti-TIGIT bispecific's run…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Bristol Myers Squibb obtained an exclusive global license to Agenus' AGEN1777, a TIGIT-targeting bispecific antibody program. Agenus received $200M upfront and is eligible for up to $1.36B in development, regulatory and commercial milestones plus tiered double-digit royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Agenus Inc. (this deal) | 2021 | $1.6B | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2021 deals · Bristol-Myers Squibb Company deals · Oncology deals